JCT  Vol.4 No.1 A , January 2013
Relevance of Surgery in Stage IV Gastric Carcinoma
Abstract: New anticancer drugs are being increasingly used for advanced and recurrent gastric cancer in many institutions. Therefore, the relative importance of surgery may have changed, and there may also be controversy as to whether patients with stage IV gastric cancer should or not undergo surgical resection. The relevance of surgery in this population was studied. The relevance of surgery was studied in 304 cases of stage IV gastric cancer who were treated at KurumeUniversityHospitalfrom 1995 to 2009. Multivariate analysis showed that distant organ metastasis was significantly correlated with surgery. In stage IV cases, chemotherapy and the number of stage IV factors were independent prognostic factors. In surgery cases, venous invasion, chemotherapy, and residual tumor were independent prognostic factors. R0 was significantly higher in the surgery with chemotherapy group than in the chemotherapy alone group, but there was no significant difference in R1 or R2 cases between the surgery with chemotherapy group and the chemotherapy alone group. In R2 cases, use of a new drug was an independent prognostic factor. The rate of R0 was significantly higher in the preoperative chemotherapy group than in the surgery alone group. In preoperative chemotherapy cases, the S-1/cisplatin (CDDP) group had a 50% 2-year survival rate, and these cases underwent postoperative chemotherapy using the S-1 regimen. A multimodal treatment is considered most effective for stage IV gastric cancer, where this includes preoperative chemotherapy, surgery, and postoperative chemotherapy using the new anti-cancer drugs.
Cite this paper: K. Aoyagi, K. Kouhuji, M. Miyagi, J. Kizaki, T. Isobe, K. Hashimoto and K. Shirouzu, "Relevance of Surgery in Stage IV Gastric Carcinoma," Journal of Cancer Therapy, Vol. 4 No. 1, 2013, pp. 6-15. doi: 10.4236/jct.2013.41A002.

[1]   D. M. Parkin, F. Bray, J. Ferlay and P. Pisani, “Global Cancer Statistics, 2002,” A Cancer Journal for Clinicians, Vol. 55, No. 2, 2005, pp. 74-108. doi:10.3322/canjclin.55.2.74

[2]   S. Lim, B. E. Muhs, S. G. Marcus, E. Newman, R. S. Berman and S. P. Hiotis, “Results Following Resection for Stage IV Gastric Cancer; Are Better Outcomes Observed in Selected Patient Subgroups?” Journal of Surgical Oncology, Vol. 95, No. 2, 2007, pp. 118-122. doi:10.1002/jso.20328

[3]   S. Maekawa, M. Saku, Y. Maehara, N. Sadanaga, K. Ikejiri, H. Anai, H. Kuwano and K. Sugimachi, “Surgical Treatment for Advanced Gastric Cancer,” Hepatogastroenterology, Vol. 43, No. 7, 1996, pp. 178-186.

[4]   F. Bozzetti, G. Bonfanti, R. A. Audisio, R. Doci, G. Dossena, L. Gennari and S. Andreola, “Prognosis of Patients after Palliative Surgical Procedures for Carcinoma of the Stomach,” The Journal of Surgery, Gynecology and Obstetrics, Vol. 164, No. 2, 1987, pp. 151-154.

[5]   H. H. Hartgrink, H. Putter, E. Klein Kranenbarg, J. J. Bonenkamp and C. J. van de Velde, “Value of Palliative Resection in Gastric Cancer,” British Journal of Surgery, Vol. 89, No. 11, 2002, pp. 1438-1443. doi:10.1046/j.1365-2168.2002.02220.x

[6]   J. J. Bonenkamp, M. Sasako, J. Hermans and C. J. van de Velde, “Tumor Load and Surgical Palliation in Gastric Cancer,” Hepatogastroenterology, Vol. 48, No. 41, 2001, pp. 1219-1221.

[7]   Japanese Gastric Cancer Association, “Japanese Classification of Gastric Carcinoma, 2nd English Edition,” Gastric Cancer, Vol. 1, No.1, 1998, pp. 10-24.

[8]   Japanese Gastric Cancer Association, “Japanese Classification of Gastric Carvinoma, 3rd English Edition,” Gastric Cancer, Vol. 14, No. 2, 2011, pp. 101-112. doi:10.1007/s10120-011-0041-5

[9]   Japanese Gastric Cancer Association, “Japanese Gastric Cancer Treatment Guideline 2010 (ver. 3),” Gastric Cancer, Vol. 14, No. 2, 2011, pp. 113-123. doi:10.1007/s10120-011-0042-4

[10]   Y. Maehara, “S-1 in Gastric Cancer: A Comprehensive Review,” Gastric Cancer, Vol. 6, Suppl. 1, 2003, pp. 2-8. doi:10.1007/s10120-003-0232-9

[11]   S. Sakuramoto, M. Sasako, T. Yamaguchi, T. Kinoshita, M. Fujii, A. Nashimoto, H. Furukawa, T. Nakajima, Y. Ohashi, H. Imamura, M. Higashino, Y. Yamamura, A. Kurita and K. Arai, “Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine,” The New England Journal of Medicine, Vol. 357, No. 18, 2007, pp. 1810-1820. doi:10.1056/NEJMoa072252

[12]   Y. Emi, M. Yamamoto, I. Takahashi, H. Orita, Y. Kakeji, S. Kohnoe and Y. Maehara, “Phase II Study of Weekly Paclitaxel by One-Hour Infusion for Advanced Gastric Cancer,” Surgery Today, Vol. 38, No. 11, 2008, pp. 1013-1020. doi:10.1007/s00595-008-3769-8

[13]   M. Nishiyama and S. Wada, “Docetaxel: Its Role in Current and Future Treatments for Advanced Gastric Cancer,” Gastric Cancer, Vol. 12, No. 3, 2009, pp. 132-141. doi:10.1007/s10120-009-0521-z

[14]   E. Van Cutsem, D. Haller and A. Ohtsu, “The Role of Chemotherapy in Current Treatment of Gastric Cancer,” Gastric Cancer, Vol. 5, Suppl. 1, 2002, pp. 17-22. doi:10.1007/s10120-002-0219-y

[15]   W. Koizumi, H. Narahara, T. Hara, A. Takagane, T. Akiya, M. Takagi, K. Miyashita, T. Nishizaki, O. Kobayashi, W. Takiyama, Y. Toh, T. Nagaie, S. Takagi, Y. Yamamura, K. Yanaoka, H. Orita and M. Takeuchi, “S-1 plus Cisplatin versus S-1 Alone for First-Line Treatment of Advanced Gastric Cancer (SPIRITS trial): A Phase III Trial,” The Lancet Oncology, Vol. 9, No. 3, 2008, pp. 215-221. doi:10.1016/S1470-2045(08)70035-4

[16]   A. Nashimoto, H. Yabusaki, S. Nakagawa, Y. Takii, Y. Tsuchiya and T. Otsuo, “Preoperative Chemotherapy with S-1 and Cisplatin for Highly Advanced Gastric Cancer,” Anticancer Research, Vol. 29, No. 11, 2009, pp. 4689-4696.

[17]   M. Fujii, M. Kochi and T. Takayama, “Recent Advances in Chemotherapy for Advanced Gastric Cancer in Japan,” Surgery Today, Vol. 40, No. 4, 2010, pp. 295-300. doi:10.1007/s00595-009-4148-9

[18]   Y. J. Bang, E. Van Cutsem, A. Fevereislova, H. C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Rüschoff and Y. K. Kang, “Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomized Controlled Trial,” Lancet, Vol. 376, No. 9742, 2010, pp. 687-697. doi:10.1016/S0140-6736(10)61121-X

[19]   J. K. Smith, J. S. Hill, S. C. Ng, T. P. McDade, S. A. Shah and J. F. Tseng, “Potential Benefit of Resection for Stage IV Gastric Cancer: A National Survey,” Journal of Gastrointestinal Surgery, Vol. 14, No. 11, 2010, pp. 1660-1668. doi:10.1007/s11605-010-1351-3

[20]   T. Okuyama, D. Korenaga, K. Koushi, S. Itoh, H. Kawanaka, Y. Ikeda and K. Takenaka, “The Prognostic Significance of Chemotherapy for Stage IV Gastric Cancer Patients: A Single-Institution Experience,” Surgery Today, Vol. 41, No. 7, 2011, pp. 935-940. doi:10.1007/s00595-010-4403-0

[21]   M. Iwahashi, M. Nakamori, M. Tani, H. Yamaue, S. Sakaguchi, M. Nakamura, K. Ueda, M. Ichiro, E. Nishio and H. Tanimura, “Complete Response of Highly Advanced Gastric Cancer with Peritoneal Dissemination after New Combined Chemotherapy of S-1 and Low-Dose Cisplatin: Report of a Case,” Oncology, Vol. 61, No. 1, 2001, pp. 16-22. doi:10.1159/000055347

[22]   N. Yoshimizu, Y. Saikawa, T. Kubota, Y. Akiba, M. Yoshida, Y. Otani, K. Kumai, T. Hibi and M. Kitajima, “Complete Response of a Highly Advanced Gastric Carcinoma to Preoperative Chemoradiotherapy with S-1 and Low Dose Cisplatin,” Gastric Cancer, Vol. 6, No. 3, 2003, pp. 185-190. doi:10.1007/s10120-003-0239-2

[23]   I. Yoshida, Y. Sakurai, Y. Komori, S. Tonomura, T. Masui, M. Shoji, Y. Nakamura, H. Imazu, I. Uyama and M. Ochiai, “Successful Downstaging by S-1 Based Chemotherapy Followed by Surgical Resections for Gastric Carcinoma with Extensive Distant Lymph Node Metastasis-Report of Two Cases and a Review of Cases with Surgical Resection after Downstaging by S-1 Based Chemotherapy,” Hepatogastroenterology Vol. 52, No. 63, 2005, pp. 978-984.

[24]   A. Tsuburaya, “Adjuvant Chemotherapy for Gastric Cancer: Current Status and Future Perspective,” Gastroenterological Surgery, Vol. 35, No. 2, 2012, pp. 193-200.

[25]   T. Kanda, K. Yajima, S. Kosugi, T. Ishikawa, Y. Ajioka and K. Hatakeyama, “Gastrectomy as a Secondary Surgery for Stage IV Gastric Cancer Patients Who Underwent S-1-Based Chemotherapy: A Multi-Institute Retrospective Study,” Gastric Cancer, Vol. 15, No. 3, 2012, pp. 235-244. doi:10.1007/s10120-011-0100-y

[26]   K. Oyama, S. Fushida, J. Kinoshita, I. Makino, K. Nakamura, H. Hayashi, H. Nakagawara, H. Tajima, H. Fujita, H. Takamura, I. Ninomiya, H. Kitagawa, T. Tani, T. Fujimura and T. Ohta, “Efficacy of Pre-Operative Chemotherapy with Docetaxel, Cisplatin, and S-1 (DCS Therapy) and Curative Resection for Gastric Cancer with Pathologically Positive Para-Aortic Lymph Nodes,” Journal of Surgical Oncology, Vol. 105, No. 6, 2012, pp. 535-541. doi:10.1002/jso.22125